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prostate volume and volume that received 100% of the prescribed iso-
dose, respectively) achieved in glands ≥ 60 cc were not significantly 
different compared to those with glands < 60 cc (p≥ 0.2). Nonetheless, 
biochemical control of disease in patients with larger CTV was 
significantly higher (91% vs 78% at 6 years; p = 0.004). In uni and 
multivariate analysis, CTV was a significant predictor for risk of 
biochemical relapse. This was not at the expense of an increase in 
either moderate (p = 0.6) or severe (p = 0.3) late genitourinary 
toxicity. Usage of hormonal therapy was 17% lower in the large gland 
group (p = 0.01). There was no significant difference in FFbR or in the 
incidence of late genitourinary or rectal morbidity between the three 
fractionation schedules. 
 
  
Conclusions: Prostate gland size does not affect dosimetric 
parameters in HDR-BT assessed by D90 and V100. In patients with 
larger prostate glands a significantly higher biochemical control of 
disease has been observed with no difference in late toxicity. This 
improvement cannot be attributed to differences in dosimetry. Gland 
size should not be considered when selecting patients for HDR-BT.  
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Purpose/Objective: Even though calcifications are observed in clinical 
practice, the actual dose calculation algorithm (TG-43) overrides 
them with water material and density. However, it is a known fact 
that at low energy in LDR seed implants the cross section depends 
strongly on the effective atomic number, increasing the probability of 
important dose discrepancies around the calcified regions. It is 
hypothesized that significant effects on the dose metrics such as the 
dose volume histogram (DVH), target volume and urethra are not 
taken into accounts. This study investigates these effects on delivered 
dose from calcifications in post-implant dosimetry.  
Materials and Methods: 42 patients with visible calcifications in the 
prostate were identified. Threshold segmentation is used to 
distinguish normal prostate tissue from calcification. Monte Carlo (MC) 
simulations are made with the Geant4-based ALGEBRA software [1] in 
1mm3 voxels. Materials are assigned based on TG-186 recom-
mendations and the sources are explicitly modeled. Breast 
calcification definition is used to define the prostate calcification with 
density taken from the CT numbers. We identified 6 different dose 
calculation scenarios for our study: MC in water with (1) and without 
(2) seeds, 2) MC in a water prostate with densities from the CT but 
with calcification areas with (3) and without seeds (4) and finally full 
tissue heterogeneities with (5) and without seeds (6).  
Results: Relative to the TG-43 algorithm, we measure large 
differences, up to -27 (-28)% on the D90 (V100) with full tissue 
heterogeneities and seeds modeled, and up to -25 (-22)% when only 
the calcificified areas and seeds are taken into account. The negative 
sign indicated a decrease in dose relative to TG-43. Calcifications, 
inter-seed attenuation and tissue heterogeneities can lead to 
interplay phenomena. Hot-spot regions as defined by V200 are the 
most affected, with difference to TG-43 up to -74%. The urethra also 
shows significant dose discrepancies depending on the location of the 
calcifications. Urethra D90 differences of -17% relative to full MC 
calculations are observed, -10% considering calcification only. For all 
cases under investigation, the average decrease of D90 is -15% for the 
prostate and -8% for the urethra.  
Conclusions: Taking into account tissue heterogeneities, composition, 
and calcifications composition produces the highest change relative to 
TG-43. Based on the patient cohort, calcifications have a measurable 
impact on the target volume dose parameters and also may bring a 
significant decrease in the delivered dose to the urethra. The real 
composition of the prostate calcification remains to be determined to 
establish a better understanding ofthe dosimetric consequences. 
[1] Afsharpour, et al, 'ALGEBRA: ALgorithm for the Heterogeneous 
Dosimetry Based on GEANT4 for BRAchytherapy.' Physics in Medicine 
andBiology 57, no. 11 (June 7, 2012): 3273–3280.doi:10.1088/0031-
9155/57/11/3273. 
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Purpose/Objective: MRI provides the gold standard for tumour 
delineation in gynaecological brachytherapy. While traditionally CT 
has been used for applicator reconstruction and then fused with MRI, 
in recent years the use of MRI only for the reconstruction of 
applicators, with or without MRI compatible line markers, has become 
more widespread. The purpose of this study is to evaluate the inter-
operator differences in DVH parameters for OAR and HR-CTV when 
reconstructing titanium applicators with a fixed geometry, based only 
on T2 MRI images. Line markers are not currently commercially 
available for this applicator type. GEC-ESTRO recommendations 
regarding HR-CTV were followed and identical library plans used, 
prescribing to point A. 
Materials and Methods: Three patient plans using an identical OAR 
and HR-CTV structure set were used to retrospectively reconstruct a 
titanium Rotterdam type applicator using a 3D library model. Eight 
regular planners (radiographers, medical physicists and dosimetrists) 
independently reconstructed applicators and set an origin point based 
upon the applicator model. Identical library plans were loaded onto 
each applicator and the variations in DVH parameters for both HR-CTV 
and OAR assessed. 
Results: Co-ordinate positions of point A were used as a surrogate for 
applicator model alignment to the applicator image. Vector 
differences between eight regular planners were assessed by 
comparing the average co-ordinates of point A between all of the 
plans. The vector differences between the co-ordinates, compared 
against the average co-ordinates, show that the mean absolute 
difference between planners is 1.0mm (SD 0.4mm). All values were 
within 2mm, which shows good agreement between planners.  
The average percentage absolute-differences in DVH parameters 
arising from these variations, when compared against the average 
value for each, can be seen in Table 1. 
 
Table 1 
These results show that the average absolute differences are very low 
(<=3.3%), with the highest difference being for the HR-CTV D100%, 
which is known to be less reproducible than the D98% for HR-CTV.  
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Overall the D2cc values for the OAR have a lower percentage 
difference between planners than the D0.1cc due to the increased 
influence within the small volume. 
Conclusions: T2 MR imaging alone for reconstruction, using the 
external applicator surface, is reproducible between different 
planners. Slice thickness and inter-space gap are known parameters 
that can lead to uncertainties in applicator reconstruction, but by 
using mutual information from orthogonal sequences these 
uncertainties can be minimised. 
The changes in DVH parameters between planners are small, for both 
HR-CTV and all OARs, and would not result in a clinically significant 
change in terms of optimisation approach for the treatment plan. 
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Purpose/Objective: For brachytherapy of cervical cancers, the 
imaging modality of choice for delineation of targets and organ at 
risks (OAR) is T2-weighted MR imaging. Applicator reconstruction using 
MR imaging can be problematic for applicators composed of titanium. 
Titanium generates susceptibility artefacts on MR scans, causing signal 
voids near the titanium that may hamper applicator reconstruction. 
The goal of this study is to propose a novel MR sequence that yields 
non-deformed, high resolution and high contrast images that can be 
used for accurate and reproducible reconstruction of titanium 
applicators. The method is tested using a new design of the tandem 
and ovoid titanium Rotterdam applicator (Nucletron). 
Materials and Methods: A 1.5 Tesla MR scanner was used with a 3D 
radiofrequency Spoiled Gradient Recalled Echo sequence (SPGR, TE: 
1.1 ms, TR: 2.5, voxel size: 1.4x1.4x1.6 mm3, flip angle: 3o, number of 
excitations: 3) for imaging and applicator reconstruction. The 
geometrical accuracy of the applicator in the images was assessed 
using an in house developed gel filled phantom that could fixate the 
applicator. The inter-observer variability of applicator reconstruction 
was studied by analysing the results of eight different technicians that 
each performed applicator reconstruction for four different patients. 
The rigidity of the applicator allowed the use of a single library 
applicator, a digital model of the applicator with fixed dimensions, for 
applicator reconstruction. 
Results: On a standard T2 weighted scan, the titanium did not 
produce artefacts that hampered tumour delineation, but the contrast 
between the applicator and uterus was not sufficient for accurate 
applicator reconstructions. The 3D SPGR scan sequence yielded an 
excellent contrast between the soft tissues and the applicator, which 
was clearly visible as a signal void. When the intra-uterine was aligned 
with the B0 field,the width (FWHM) of its signal void was exactly 
equal to the real diameter of 3.0 mm, but it increased to 6.2 mm 
when the intra-uterine was tilted 46ocompared to the B0 field. 
Because the intra-uterine tube was located in the centre of the signal 
void (within 0.7 mm), the accuracy of applicator reconstruction was 
not affected by the expansion of the signal void for large tilt 
angles.This was confirmed by the excellent inter-observer variability 
among the eight technicians. The mean deviation for all reconstructed 
dwell positions was smaller than 1.0 mm and the maximum deviation 
of any dwell position among all patients and technicians was only 1.7 
mm. 
Conclusions: The titanium applicator was clearly visible on the 3D 
SPGR MR images, allowing applicator reconstruction with excellent 
accuracy and reproducibility. When used in addition to the standard 
T2 weighted MR images for tumour and OAR delineation, high 
accuracy MR guided brachytherapy is feasible with a titanium 
applicator. 
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Purpose/Objective: To compare the uncertainties of CT and MRI-T1 
based seed reconstruction in post-implant evaluation of permanent 
prostate brachytherapy in terms of interobserver variability, and to 
quantify the impact of this seed detection variability on a selection of 
dosimetric parameters for three postplan techniques: 1) CT only, 2) 
MRI-T1 fused with MRI-T2, and 3) CT fused with MRI-T2. 
Materials and Methods: Seven physicists reconstructed the seed 
positions on post-implant CT and MRI-T1 weighted images of three 
patients treated with I-125 seed brachytherapy. A reference seed set 
was defined by two experienced physicists. The reconstructed seeds 
were assigned to the reference seeds within an acceptance diameter 
of 15mm, using a dedicated Matlab program. For each patient and 
imaging modality the interobserver variability was calculated with 
respect to the reference (1 SDref). The effect of this variability on 
dosimetry (D90, V100, V150) was calculated for CT and for CT + MRI-T2 
(both techniques using CT based seed reconstruction), as well as for 
MRI-T1 + MRI-T2 (using MRI-T1 based seed reconstruction), for a fixed 
CT and MRI-T2 prostate contour. Contouring was done by two 
experienced uro-radiologists based on the post-implant CTV-P(rostate) 
definition according to the ESTRO/EAU/EORTC prostate recom-
mendations. 
Results: For CT, on average 98 % of the reconstructed seeds could be 
assigned to a reference seed, while the mean seed assignment rate for 
T1 was 93 %. Averaged over three patients, the interobserver 
variability in CT based seed reconstruction was 1.1 mm (1 SDref). This 
resulted in D90 variabilities < 2% (1 SDref) for CT and CT + MRI-T2, 
which is clinically acceptable (see table). Also the interobserver 
variabilities in V100 and V150 were small, with patient mean SDref values 
< 1% and < 4% respectively.  
The mean interobserver variability in MRI based seed reconstruction 
was 3.0 mm (1 SDref). This would be even larger if non-assigned seeds 
(outside the acceptance diameter) would be taken into account. The 
larger seed detection uncertainties on MRI-T1 compared to CT are due 
to the lack of an automated seed finder tool, and the fact that seeds 
are less clearly depicted on MRI. The impact of the interobserver 
variability on D90 was 6.6% for MRI-T1 + MRI-T2. 
Conclusions: Seed reconstruction on MRI-T1-weighted images was less 
accurate than on CT. This difference in uncertainties should be taken 
into account and weighted against uncertainties due to contouring and 
image fusion when comparing the overall reliability of postplan 
techniques. 
Table: Interobserver variability in seed reconstruction (averaged over 
three patients), expressed as (a) positional deviation (mm) and (b) 
dosimetric impact (%) with respect to the reference values. 
 
SDref in seed reconstruction (mm) CT MR-T1 
 1.1 mm 3.0 mm SDref in dosimetry (%) CT CT + MR-T2MR-T1 + MR-T2 
D90 
V100 
V150 
1.5 
0.9 
3.6 
1.3 
0.5 
3.2 
6.6 
2.8 
8.1 
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Purpose/Objective: The current clinical low dose rate (LDR) 
brachytherapy dosimetry protocol for low energy photons, AAPM 
TG43, ignores the effects of tissue composition. Given the 
photoelectric effect's dominance at the low photon energies, the 
dosimetry is dependent on the elemental composition and density of 
tissues. AAPM TG186 recently recommended that brachytherapy dose 
calculations take heterogeneities into account by using CT images. In 
LDR seed implants, metal streaking artefacts degrade density (ρ) 
information and limit the applicability of heterogeneity corrections. 
Metal artefact reduction (MAR) techniques have been presented, but 
are currently not clinically implemented in radiotherapy, possibly due 
to their complexity. Dual energy CT (DECT) imaging allows the 
reconstruction of mono energetic attenuation maps over a range of 
diagnostic energies. It has recently been shown that by carefully 
